Publicaciones en colaboración con investigadores/as de Universitat Rovira i Virgili (17)

2022

  1. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

    Frontiers in Cellular and Infection Microbiology, Vol. 12

2020

  1. Clinical predictive model of multidrug resistance in neutropenic cancer patients with bloodstream infection due to Pseudomonas aeruginosa

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 4

2018

  1. Developing collaborative works for faster progress on fungal respiratory infections in cystic fibrosis

    Medical Mycology, Vol. 56, pp. S42-S59

2011

  1. Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: In vitro activity, (1→3)-β-D-glucan and mannan serum levels, histopathological findings, and In Vivo efficacy

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 4985-4989

  2. Guidelines for the treatment of invasive fungal disease by Aspergillus spp. and other fungi issued by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). 2011 Update

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 6, pp. 435-454

  3. Saccharomyces cerevisiae Vaginitis: Microbiology and In Vitro Antifungal Susceptibility

    Mycopathologia, Vol. 172, Núm. 3, pp. 201-205

  4. Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) guidelines for the diagnosis of invasive fungal infections. 2010 Update

    Enfermedades Infecciosas y Microbiologia Clinica

2009

  1. Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy

    Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 12, pp. 5297-5299

2008

  1. In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.

    Antimicrobial Agents and Chemotherapy, Vol. 52, Núm. 4, pp. 1529-1532

  2. Isolation of Candida africana, probable atypical strains of Candida albicans, from a patient with vaginitis

    Medical Mycology, Vol. 46, Núm. 2, pp. 167-170

  3. Terbinafine susceptibility patterns for onychomycosis-causative dermatophytes and Scopulariopsis brevicaulis

    International Journal of Antimicrobial Agents, Vol. 31, Núm. 6, pp. 540-543

2007

  1. In vitro activity of micafungin combined with itraconazole against Candida spp.

    International Journal of Antimicrobial Agents, Vol. 30, Núm. 5, pp. 463-465

  2. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis

    International Journal of Antimicrobial Agents, Vol. 30, Núm. 2, pp. 157-161

  3. In vitro interaction of micafungin and fluconazole against Candida [12]

    Journal of Antimicrobial Chemotherapy

2005

  1. Amphotericin B colloidal dispersion. Survey of in vitro antifungal activity. Antifungal activity of Amphocil®, amphotericin B and fluconazole

    Mikologia Lekarska, Vol. 12, Núm. 1, pp. 5-10

2002

  1. Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P

    Chemotherapy, Vol. 48, Núm. 4-5, pp. 224-231

1997

  1. Characterization of Scedosporium prolificans clinical isolates by randomly amplified polymorphic DNA analysis

    Journal of Clinical Microbiology, Vol. 35, Núm. 9, pp. 2270-2274